pharmaphorum

JUNE 12, 2025

These closures, compounded by the decline of independent pharmacies, create a critical gap in care. R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems. pharmaphorum – an EVERSANA company

Health and Personal Care Stores 59

Health and Personal Care Stores Diabetes Pharmaceutical Companies Pharmaceutical Companies 59

pharmaphorum

JULY 14, 2025

R&D Life Sciences Industry Report - Biologics and Generics The importance of biosimilars only continues to grow, driven by the potential savings they are able to deliver to healthcare systems. Website and content copyright © 2009- 2025 , pharmaphorum media limited or its licensors; all rights reserved.

Diabetes 52

Diabetes Pharmaceutical Companies Pharmaceutical Companies Biosimilars 52

Eye on FDA

FEBRUARY 10, 2021

Heightened Role for “Bad Ad Program” – A recent interview with the new Acting Director of OPDP revealed that a primary focus for the office this past year was in relation to the biosimilars market. It was also noted that the “ Bad Ad ” program turned 10 years old this year.

Communication 77

Communication Biosimilars Compounding 77

PharmaShots

JUNE 28, 2023

In 2009, Pfizer acquired Wyeth thus seeking the rights to Enbrel. Consistent with prior periods, Enbrel continued to lose market share, and this decline was compounded by a reduction in the growth rate of the rheumatology market as a result of COVID-19. Enbrel biosimilars Gabionline.net Centerforbiosimilars.com 7.

Biosimilars 40

Biosimilars Insurance Coverage and Processing Dosage Compounding 40

Pharmacy Times

JUNE 19, 2025

With this action, nitisinone is the first and only FDA-approved treatment for AKU. 1 AKU, also known as black urine disease, is a rare inherited disorder that prevents the patient’s body from completely breaking down 2 amino acids, tyrosine and phenylalanine.

Pharmacy Technician 38

Pharmacy Technician Compounding Pharmacies Pharmacy Management Immunization 38

PharmaTech

JUNE 24, 2025

Ethris GmbH was founded in Germany in 2009 and is a clinical-stage biotechnology company developing next-generation RNA therapeutics and vaccines based on non-immunogenic messenger RNA (SNIM RNA) and lipidoid nanoparticle (SNaPL). billion by 2034, exhibiting a compound average growth rate of 1.2% during 2025–2034 (26).

Vaccines 59

Vaccines Dosage Drug Development Immunization 59

pharmaphorum

DECEMBER 2, 2020

It was at this time they set their site at Sandwich in the UK, initially just to finish processing compounds imported from America, but due to tariffs on imported products the company rapidly expanded the plant to accommodate producing medicines from scratch. Likewise, tanezumab, an anti-osteoarthritic, failed in trials.

Compounding 128

Compounding Vaccines Biosimilars Pharmaceutical Companies 128